None

Arrowhead completes enrollment in phase 1b trial of CALAA-01 in solid tumors

Through its Calando Pharmaceuticals subsidiary, Arrowhead Research, a clinical stage targeted therapeutics company based in Pasadena, Calif., has completed enrollment of a phase 1b clinical trial of C...

Enrollment complete in Arrowhead’s CALAA-01 phase 1b trial on solid tumors

Arrowhead Research Corporation, a targeted therapeutics company, today announced that, through its Calando Pharmaceuticals subsidiary, it has completed enrollment of a phase 1b clinical trial of CALAA...

CALAA-01: Completed Phase Ib enrollment

Arrowhead Completes Enrollment in Phase 1b Trial of RNAi Drug Candidate CALAA-01

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that, through its Calando Pharmaceuticals subsidiary, it has completed enrollment o...

Arrowhead Reports Fiscal 2012 Fourth Quarter and Year-End Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced financial results for its fiscal 2012 fourth quarter and year ended September 30, 2...

Arrowhead Presents Data on DPC System at TIDES 2012

Arrowhead Research Corporation (NASDAQ:ARWR) today announced that Darren Wakefield, Ph.D., one of its Senior Scientists at its Madison, WI research and development facility presen...

Arrowhead Reports Fiscal 2012 Third Quarter Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced financial results for its fiscal 2012 third quarter ended June 30, 2012....

None